Hemadsorption therapy in critically ill patients – double blind bet?

Czech version

Authors: J. Horák ^1,2; J. Chvojka ^1,2; V. Tégl ^2,3; L. Nalos ^2,4; M. Peltanová ^2,3; J. Beneš ^2,3; M. Matějovič ^1,2
Authors‘ workplace: I. interní klinika, Lékařská fakulta v Plzni, Univerzita Karlova a Fakultní nemocnice Plzeň ¹; Biomedicínské centrum, Lékařská fakulta v Plzni, Univerzita Karlova ²; Klinika anesteziologie, resuscitace a intenzivní medicíny, Lékařská fakulta v Plzni, Univerzita Karlova, a Fakultní nemocnice Plzeň ³; Ústav fyziologie, Lékařská fakulta v Plzni, Univerzita Karlova ⁴
Published in: Anest. intenziv. Med., 31, 2020, č. 4, s. 172-175
Category: Review Articles

Overview

Recently, the therapeutic approach using the extracorporeal hemadsorption technologies attracted much attention. Effort to affect the patophysiological processess associated with critical illness represents an attractive concept, that penetrates into clinical practice. Here we present the critical opinion on current status of hemadsorption therapy in critical ill patients in the context of published evidence.

Keywords:

hemadsorption – sepsis – critical illness – CytoSorb – oXiris

Sources

1. Basu R, Pathak S, Goyal J, Chaudhry R, Goel RB, Barwal A. Use of a novel hemoadsorption device for cytokine removal as adjuvant therapy in a patient with septic shock with multi‑organ dysfunction: A case study. Ind J Crit Care Med. 2014; 18: 822–824. doi. org/10.4103/0972-5229.146321

2. Hinz B, Jauch O, Noky T, Friesecke S, Abel P, Kaiser R. CytoSorb, a novel therapeuticapproach for patients with septic shock: a case report. Int J Artif Org. 2015; 38(8): 461–464. doi.org/10.5301/ijao.5000429

3. Steltzer H, Grieb A, Mostafa K, Berger R. Use of CytoSorb in Traumatic Amputation of the Forearm and Severe Septic Shock. Case Rep Crit Care. 2017: 8747616. doi. org/10.1155/2017/8747616

4. Kogelmann K, Jarczak D, Scheller M, Druner M. Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care. 2017; 21(1): 74. doi.org/10.1186/s13054-017-1662-9

5. Born F, Pichlmaier M, Peterß S, Khaladj N, Hagl C. Systemic Inflammatory ResponseSyndrome in der Herzchirurgie: Neue Therapiemöglichkeiten durch den Einsatz eines Cytokin‑Adsorpers während EKZ. Kardiotechnik. 2014; 23(2): 41–46.

6. Linden K, Scaravilli V, Kreyer SFX, Belenkiy SM, Stewart IJ, Chung KK, et al. Evaluation of the Cytosorb Hemoadsorptive Column in a Pig Model of Severe Smoke and Burn Injury. Shock. 2015; 44(5): 487–495. doi.org/10.1097/SHK.0000000000000439

7. Brouwer WP, Duran S, Kuijper M, Ince C. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all‑ cause mortality in ICU patients with septic shock: a propensity‑score‑weighted retrospective study. Crit Care. 2019; 23(1): 317. doi. org/10.1186/s13054-019-2588-1

8. Schadler D, Pausch C, Heise D, Meier‑Hellmann A, Brederlau J, Weiler N, et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial. PloS One. 2017; 12(10): e0187015. doi.org/10.1371/ journal.pone.0187015

9. Friesecke S, Stecher SS, Gross S, Felix SB, Nierhaus A. Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single‑ center study. J Artif Org. 2017; 20(3): 252–259. doi.org/10.1007/s10047-017-0967-4

10. Zuccari S, Damiani E, Domizi R, Scorcella C, D’Arezzo M, Carsetti A, et al. Changes in Cytokines, Haemodynamics and Microcirculation in Patients with Sepsis/Septic Shock Undergoing Continuous Renal Replacement Therapy and Blood Purification with Cyto- Sorb. Blood Purif. 2019: 1–7. doi.org/10.1159/000502540

11. Kacar CK, Uzundere O, Kandemir D, Yektas A. Efficacy of HA330 Hemoperfusion Adsorpent in Patients Followed in the Intensive Care Unit for Septic Shock and Acute Kidney Injury and Treated with Continuous Venovenous Hemodiafiltration as Renal Replacement Therapy. Blood Purif. 2020; 1–9. doi.org/10.1159/000505565

12. Datzmann T, Träger K. Extracorporeal membrane oxygenation and cytokine adsorption. J Thorac, DiS. 2018; 10(S5 Suppl 5): 653–660.

13. Bruenger F, Kizner L, Weile J, Morshuis M, Gummert JF. First successful combination of ECMO with cytokine removal therapy in cardiogenic septic shock: a case report. Int J Artif Organs. 2015; 38(2): 113–116.

14. Chvojka J, Martinkova V, Benes J, Valesova L, Danihel V, Nalos L, et al. Mechanical circulatory support in refractory vasodilatory septic shock: A randomized controlled porcine study. Shock. 2020; 53(1): 124–131.

15. Angheloiu AA, Angheloiu GO. Removal of dabigatran using sorbent hemadsorption. Int J Cardiol. 2019; 293: 73–75. doi.org/10.1016/j.ijcard.2019. 06. 078

16. Hassan K, Kannmacher J, Wohlmuth P, Budde U, Schmoeckel M, Geidel S. Cytosorb Adsorption During Emergency Cardiac Operations in Patients at High Risk of Bleeding. Ann Thor Surg. 2019; 108(1): 45–51. doi.org/10.1016/j.athoracsur.2018. 12. 032

17. Giuntoli L, Dalmastri V, Cilloni N, Orsi C, Stalteri L, Demelas V, et al. Severe quetiapine voluntary overdose successfully treated with a new hemoperfusion sorbent. Int J Artif Org. 2019; 42(9): 516–520. doi.org/10.1177/0391398819837686

18. Stibor B. Použití cytokinových filtrů na ICU – kdy, komu a jak? Colours of Sepsis [přednáška]. 2020 [cit. 2020-4-22]. Dostupné z: http://www.sepseostrava.cz/sepse/sbornik/2020/2. Pou.it.cytokinov.ch.filtr…kdy.komu.a.jak.pdf

19. Poli EC, Simoni C, Andre P, Buclin T, Longchamp D, Perez MH, Schneider AG. Clindamycin clearance during Cytosorb hemoadsorption: A case report and pharmacokinetic study. Int J Artif Org. 2019; 42(5): 258–262. doi.org/10.1177/0391398819831303

20. Konig C, Rohr AC, Frey OR, Brinkmann A, Roberts JA, Wichmann D, et al. In vitro removal of anti‑ infective agents by a novel cytokine adsorpent system. Int J Artif Org. 2019; 42(2): 57–64. doi.org/10.1177/0391398818812601

21. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009; 301(23): 2445–2452. doi.org/10.1001/jama.2009.856

22. Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015; 41(6): 975–984. doi.org/10.1007/ s00134-015-3751-z

23. Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, et al. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial. JAMA, 2018; 320(14): 1455–1463. doi.org/10.1001/jama.2018.14618

24. Klein DJ, Foster D, Walker PM, Bagshaw SM, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 2018; 44(12): 2205–2212. doi.org/10.1007/s00134-018-5463-7

25. Broman ME, Hansson F, Vincent JL, Bodelsson M. Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: A randomized crossover double‑blind study. PloS One. 2019; 14(8): e0220444. doi.org/10.1371/journal.pone.0220444

26. Schwindenhammer V, Girardot T, Chaulier K, Gregoire A, Monard C, Huriaux L, et al. oXiris( R) Use in Septic Shock: Experience of Two French Centres. Blood Purif. 2019; 47(Suppl 3): 1–7. doi.org/10.1159/000499510

27. Hawchar F, Laszlo I, Oveges N, Trasy D, Ondrik Z, Molnar Z. Extracorporeal cytokine adsorption in septic shock: A proof of concept randomized, controlled pilot study. J Crit Care. 2019; 49: 172–178. doi.org/10.1016/j.jcrc.2018. 11. 003

28. Mlinaric A, Horvat M, Supak Smolcic V. Dealing with the positive publication bias: Why you should really publish your negative results. Biochem Medica. 2017; 27(3): 30201. doi. org/10.11613/BM.2017.030201

29. Minne L, Abu‑Hanna A, de Jonge E. Evaluation of SOFA‑based models for predicting mortality in the ICU: A systematic review. Crit Care. 2008; 12(6): 161. doi.org/10.1186/cc7160

30. Poncet A, Perneger TV, Merlani P, Capuzzo M, Combescure C. Determinants of the calibration of SAPS II and SAPS 3 mortality scores in intensive care: a European multicenter study. Crit Care. 2017; 21(1): 85. doi.org/10.1186/s13054-017-1673-6